What are the thromboembolism prevention and treatment guidelines in patients with coronavirus disease 2019 (COVID-19)?

Updated: Jun 25, 2021
  • Author: David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

American College of Chest Physicians

Guideline summary is as follows: [367]

  • In the absence of contraindications, all acutely hospitalized patients with COVID-19 should receive thromboprophylaxis therapy.
  • Low-molecular-weight heparin (LMWH) or fondaparinux should be used for thromboprophylaxis over unfractionated heparin and direct oral anticoagulants.
  • Data are insufficient to justify routine increased-intensity anticoagulant dosing in hospitalized or critically ill patients with COVID-19.
  • Recommend only inpatient thromboprophylaxis for patients with COVID-19.
  • In critically ill patients with COVID-19, suggest against routine ultrasonographic screening for asymptomatic deep vein thrombosis (DVT).
  • In critically ill patients with COVID-19 who have proximal DVT or pulmonary embolism, recommend parenteral anticoagulation therapy with therapeutic weight-adjusted LMWH or fondaparinux over unfractionated heparin.

International Society on Thrombosis and Haemostasis

Guideline summary is as follows: [368]

  • In hospitalized patients, measure D-dimers, prothrombin time, and platelet count (and possibly fibrinogen).
  • The guidelines include an algorithm for management of coagulopathy based on laboratory markers.
  • Monitoring for septic coagulopathy can be helpful in determining prognosis in patients with COVID‐19 requiring hospital admission.
  • Use of LMWH to protect critically ill patients against venous thromboembolism appears to improve prognosis.

National Institutes of Health Antithrombotic Therapy in Patients with COVID-19

Guideline summary is as follows: [369]

  • Measure hematologic and coagulation parameters (eg, D-dimers, PT, platelet count, fibrinogen) in hospitalized patients.
  • Patients on anticoagulant or antiplatelet therapies for underlying conditions should continue these medications if they receive a diagnosis of COVID-19.
  • Hospitalized adults with COVID-19 should receive VTE prophylaxis per the standard of care for other hospitalized adults.
  • Hospitalized patients with COVID-19 should not routinely be discharged on VTE prophylaxis.
  • In hospitalized patients, the possibility of thromboembolic disease should be evaluated in the event of rapid deterioration of pulmonary, cardiac, or neurological function or of sudden localized loss of peripheral perfusion.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!